Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharming Group ( (PHAR) ) has shared an announcement.
On April 2, 2026, Pharming Group N.V. announced that it has filed its 2025 Annual Report for the year ended December 31, 2025, making the document available through its dedicated annual report site and investor relations pages. The company also confirmed the submission of its 2025 Form 20-F to the U.S. Securities and Exchange Commission, a routine but important step for maintaining compliance with U.S. listing standards and providing detailed financial and operational disclosure to global investors.
These filings provide investors and other stakeholders with comprehensive insight into Pharming’s performance and strategy over 2025, reinforcing transparency as the group advances its rare-disease biopharmaceutical portfolio. The timely submission underscores Pharming’s ongoing commitment to regulatory obligations across both Euronext Amsterdam and Nasdaq, supporting its positioning as an established cross-listed player in the rare disease therapeutics market.
The most recent analyst rating on (PHAR) stock is a Hold with a $17.50 price target. To see the full list of analyst forecasts on Pharming Group stock, see the PHAR Stock Forecast page.
Spark’s Take on PHAR Stock
According to Spark, TipRanks’ AI Analyst, PHAR is a Neutral.
The score is driven primarily by improving financial performance (return to profitability and stronger cash generation) and a constructive earnings-call outlook (raised revenue guidance and stronger operating profit). These positives are tempered by weak technical momentum and a relatively high P/E with no dividend support.
To see Spark’s full report on PHAR stock, click here.
More about Pharming Group
Pharming Group N.V. is a global biopharmaceutical company focused on transforming the lives of patients with rare, debilitating, and life-threatening diseases. The Leiden-based group develops and commercializes a portfolio of innovative medicines, including small molecules and biologics, and employs a significant proportion of its workforce in the U.S.
Average Trading Volume: 28,696
Technical Sentiment Signal: Buy
Current Market Cap: $1.18B
For detailed information about PHAR stock, go to TipRanks’ Stock Analysis page.